Meet Me et the he De Deleg egates ates ! Karl Gumpper (year 4) - - PowerPoint PPT Presentation

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Me Meet et the he De Deleg egates ates!

• Karl Gumpper (year 4)
• Erin Taylor (year 3)
• Caryn Belisle (year 2)
• Jackie Maccormack-Gagnon (year 1)
• Bryan Wood (alternate, 1-year term)

• Describe the process of ASHP professional policy

development

• Identify 3 ASHP professional policies that will be

reviewed at the 2019 Annual Session of the House of Delegates

• Discuss the perspectives of MSHP members on the

issues presented

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Ob Objec ectives tives

• What is a professional policy?
• ASHP’s official stance on an issue related to pharmacy practice or the

use of medications in society

• Focuses on the right thing to do
• Serves to improve patient care and advance practice
• Based on analysis and evidence
• Importance:
• Helps develop and define pharmacy practice
• Provides direction to staff from members
• Provides direction for resource allocation
• Defines uniqueness of ASHP
• Serves as an authority for advocacy

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Po Policy cy De Develo elopment pment

Adopted from ASHP Policy Process Overview Slide deck – April 2018 (Bruce Hawkins)

• Six types of ASHP Policy
• Policy Position
• Policy Statement
• Practice Guidelines
• Therapeutic Guidelines
• Therapeutic Position Statement
• Endorsed Document

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Po Policy cy De Develo elopment pment

• These ARE intended to be:
• VOLUNTARY
• FORWARD-LOOKING
• These are NOT intended to

be:

• Law
• Regulation

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Po Policy cy Cy Cycle le

January Board of Directors Meeting February Councils Meet March Virtual House of Delegates April Board of Directors Meeting May Regional Delegate Conferences June House of Delegates Board of Directors Meeting Late June Councils Meet September Policy Week

Sources for Policy Development/Initiat ion:

• HOD

Recommendations

• HOD Resolutions
• ASHP Surveys
• Member

suggestions to Standards Mailbox

• ASHP

Sections/Forums

• ASHP Councils
• ASHP Commissions

• COUNCILS/COMMISSIONS: Create, Draft and Recommend to Board
• f Directors
• Council on Education and Workforce Development (Nicole Clark – MA/Chair)
• Council on Pharmacy Management
• Council on Pharmacy Practice
• Council on Public Policy (Chris Fortier – MA/Vice Chair, Melissa Ortega – MA)
• Council on Therapeutics (Snehal Bhatt – MA/Vice Chair)
• SECTIONS AND FORUMS:
• Section of Ambulatory Care Practitioners
• Section of Clinical Specialists and Scientists
• Section of Inpatient Care Practitioners
• Section of Pharmacy Informatics & Technology
• Section of Pharmacy Practice Managers
• New Practitioners Forum
• Pharmacy Students Forum
• Pharmacy Technician Forum

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: AS ASHP HP Pr Prof

• fes

essional sional Po Policy cy Ini nitiatio tiation

Board of Directors:

• Reviews
• Amends
• Recommends policy

positions and statements to House

• f Delegates for

approval

• Approves guidelines,

therapeutic position statements, and endorsed documents

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Re Review ew Pr Proc

• ces

ess s for

• r Ne

New w Po Policy cy

House of Delegates: (led by the Chair of the HOD)

• Review (w/input from

constituents)

• Amend (w/input from

constituents)

• Approve

Where can you find them? www.ashp.org/Pharmacy-Practice/Policy-Positions-and- Guidelines

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: AS ASHP HP Po Policy cy Po Position tions s an and d Gu Guide delines lines

• Pharmacy Expertise in Sterile Compounding
• Therapeutic Use of Cannabidiol
• Preventing Drug Product Shortages

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Po Policies cies for

• r Di

Discussion cussion

To support colleges of pharmacy in providing sterile compounding and aseptic technique instruction in didactic and experiential curricula that reflect the needs of the workforce; further, To promote the use of sterile compounding training programs to foster an increase in the number of pharmacists and pharmacy technicians with sterile compounding expertise; further, To advocate that pharmacists and pharmacy technicians who work in sterile compounding attain compounded sterile preparations advanced certifications.

AS ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Ph Phar arma macy cy Ex Expe pertis rtise e in St n Ster erile ile Co Comp mpou

• undin

nding

Let’s Discuss!

• What do you think?
• Any recommendations we should bring back?

AS ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Ph Phar arma macy cy Ex Expe pertis rtise e in St n Ster erile ile Co Comp mpou

• undin

nding

Which of the following is/are correct regarding the ASHP proposed policy for “Pharmacy Expertise in Sterile Compounding”?

A. To support colleges of pharmacy in providing sterile compounding and aseptic technique instruction in didactic and experiential curricula that reflect the needs

• f the workforce.

B. To promote the use of sterile compounding training programs to foster an increase in the number of pharmacists and pharmacy technicians with sterile compounding expertise. C. To advocate that pharmacists and pharmacy technicians who work in sterile compounding attain compounded sterile preparations advanced certifications. D. A & C only E. A, B, and C

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Se Self-Assess Assessment ment Qu Ques estio tion n #1 #1

Which of the following is/are correct regarding the ASHP proposed policy for “Pharmacy Expertise in Sterile Compounding”?

A. To support colleges of pharmacy in providing sterile compounding and aseptic technique instruction in didactic and experiential curricula that reflect the needs

• f the workforce.

B. To promote the use of sterile compounding training programs to foster an increase in the number of pharmacists and pharmacy technicians with sterile compounding expertise. C. To advocate that pharmacists and pharmacy technicians who work in sterile compounding attain compounded sterile preparations advanced certifications. D. A & C only E. A, B, and C

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Se Self-Assess Assessment ment Qu Ques estio tion n #1 #1

To support continued research on the therapeutic uses of cannabidiol (CBD); further, To provide education on the therapeutic uses of CBD; further, To oppose use of CBD-containing products not approved by the Food and Drug Administration; further, To advocate for enhanced public education regarding safe use of CBD and unapproved CBD-containing products. To recommend health systems develop policies to address patient care needs when a patient presents taking CBD- containing products.

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Th Ther erap apeut eutic ic Us Use e of

• f Ca

Cann nnab abidiol idiol

Let’s Discuss!

• What do you think?
• Any recommendations we should bring back?

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Th Ther erap apeut eutic ic Us Use e of

• f Ca

Cann nnab abidiol idiol

Which of the following is false regarding the ASHP proposed policy for “Therapeutic Use of Cannabidiol (CBD)”?

• A. To provide education on the therapeutic uses of CBD.
• B. To oppose use of all CBD-containing products.
• C. To advocate for enhanced public education regarding safe

use of CBD and unapproved CBD-containing products.

• D. To support continued research on the therapeutic uses of

CDB.

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Se Self-Assess Assessment ment Qu Ques estio tion n #2 #2

Which of the following is false regarding the ASHP proposed policy for “Therapeutic Use of Cannabidiol (CBD)”?

• A. To provide education on the therapeutic uses of CBD.
• B. To oppose use of all CBD-containing products.
• C. To advocate for enhanced public education regarding safe

use of CBD and unapproved CBD-containing products.

• D. To support continued research on the therapeutic uses of

CDB.

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Se Self-Assess Assessment ment Qu Ques estio tion n #2 #2

To advocate for ongoing federal evaluation of whether drug product shortages present risks to national security and public health; further, To advocate that drug product manufacturers be required to disclose manufacturing sites and sources of active pharmaceutical ingredients (APIs) to facilitate such a risk assessment; further, To recommend that the Food and Drug Administration (FDA) require drug product manufacturers to have contingency plans for maintaining drug supplies; further, To advocate that drug product manufacturers be required to provide a specific reason for a shortage and an estimated timeline for resolution in their Food and Drug Administration Safety and Innovation Act notifications to FDA; further, To advocate that FDA be required to publicly provide quality ratings for 503B outsourcing facilities preparing copies of drug products under the exemption for products on FDA's shortage list; further, To advocate that the Federal Trade Commission be required to evaluate the potential for drug product supply chain interruptions when considering manufacturer consolidations.

ASHP HP De Delegate ate To Town wn Ha Hall 2019: Mi Mitigati gating ng Dr Drug ug Pr Prod

• duc

uct t Sh Shor

• rtages

ages

Let’s Discuss!

• What do you think?
• Any recommendations we should bring back?

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Mi Mitigati gating ng Dr Drug ug Pr Prod

• duc

uct t Sh Shor

• rtages

ages

To better understand the risk of drug shortages to national security, the ASHP proposed policy advocates that drug manufacturers be required to disclose the following:

• A. Manufacturing sites
• B. Active pharmaceutical ingredients (APIs)
• C. Specific reasons for shortages and a timeline for resolution
• D. A and B only

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Se Self-Assess Assessment ment Qu Ques estio tion n #3 #3

To better understand the risk of drug shortages to national security, the ASHP proposed policy advocates that drug manufacturers be required to disclose the following:

• A. Manufacturing sites
• B. Active pharmaceutical ingredients (APIs)
• C. Specific reasons for shortages and a timeline for resolution
• D. A and B only

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: Se Self-Assess Assessment ment Qu Ques estio tion n #3 #3

Op Open en Fo Forum um

• Other policies discussed at RDC with mixed reactions:
• Pharmacy Technician Training and Certification (2022, ASHP/ACPE

accreditation)

• Joint Council Recommendation: Suicide Awareness and Prevention

(patient or healthcare worker, more inclusive of pharmacy workers)

• What are some other topics that should be addressed?

• ASHP’s polices are the official stance on an issue related to pharmacy

practice or the use of medications

• Councils and Commissions create, draft and recommend to the ASHP

Board of Directors then go to the ASHP House of Delegates for approval

• Delegates will take feedback to the June House of Delegates about the

polices discussed

ASHP HP De Deleg egate ate To Town wn Ha Hall 20 2019 19: In Con n Conclusion lusion